What is he best known for?
The fields of study he is best known for:
His primary areas of study are Virology, Virus, Molecular biology, Glycoprotein and Cell culture.
His research in Virology intersects with topics in Genetics, Tyrosine kinase and Reverse transcriptase.
Yoshiyuki Nagai is involved in the study of Virus that focuses on Paramyxoviridae in particular.
His work on Viral envelope as part of his general Molecular biology study is frequently connected to Factor X, thereby bridging the divide between different branches of science.
Yoshiyuki Nagai combines subjects such as Infectivity, Cell and Wild type, Mutant with his study of Cell culture.
His study looks at the relationship between Sendai virus and topics such as Myeloma protein, which overlap with Cell biology.
His most cited work include:
- p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. (385 citations)
- Roles of toll-like receptors in C-C chemokine production by renal tubular epithelial cells (224 citations)
- Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1α (SDF-1α) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage (176 citations)
What are the main themes of his work throughout his whole career to date?
Yoshiyuki Nagai mainly focuses on Virology, Virus, Sendai virus, Molecular biology and Viral replication.
His research integrates issues of RNA and Immunology, Immune system in his study of Virology.
His study in Virus is interdisciplinary in nature, drawing from both Cell culture, Antigen and Glycoprotein.
His study looks at the relationship between Sendai virus and fields such as RNA virus, as well as how they intersect with chemical problems.
The concepts of his Molecular biology study are interwoven with issues in Virus maturation, Amino acid, Cytoplasm and Gene expression.
He works mostly in the field of Viral replication, limiting it down to topics relating to Epitope and, in certain cases, Monoclonal antibody.
He most often published in these fields:
- Virology (60.00%)
- Virus (51.30%)
- Sendai virus (27.83%)
What were the highlights of his more recent work (between 2004-2017)?
- Virology (60.00%)
- Sendai virus (27.83%)
- Virus (51.30%)
In recent papers he was focusing on the following fields of study:
Yoshiyuki Nagai mostly deals with Virology, Sendai virus, Virus, Simian immunodeficiency virus and Viral replication.
His biological study spans a wide range of topics, including Immunology, Immune system and Gene.
He has included themes like Molecular biology and ESTP in his Gene study.
His Sendai virus research is multidisciplinary, relying on both Cytopathic effect, Genome and Mononegavirales.
His Simian immunodeficiency virus research incorporates elements of Gene duplication, Major histocompatibility complex and Immunodeficiency.
His studies deal with areas such as Acquired immune system, Interferon, Viral load, Paramyxoviridae and Epitope as well as Viral replication.
Between 2004 and 2017, his most popular works were:
- A Specific Region of 37 Amino Acid Residues in the SPRY (B30.2) Domain of African Green Monkey TRIM5α Determines Species-Specific Restriction of Simian Immunodeficiency Virus SIVmac Infection (113 citations)
- Rapid categorization of pathogenic Escherichia coli by multiplex PCR. (54 citations)
- Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity. (45 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Virology, Sendai virus, Gene, Healthy individuals and Biotechnology.
His Virology research includes themes of Gene duplication and Old World monkey.
His Sendai virus research is under the purview of Virus.
His Microbiology research extends to the thematically linked field of Gene.
His study brings together the fields of Outbreak and Healthy individuals.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
